概括
持续的氨酸治疗显著消耗了血抗素III (AT-III),这是一个关键的蛋白酶抑制剂. 这种减少可能解释了长期肝素治疗期间观察到的血栓栓塞并发症.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 生物化学 生物化学
背景情况:
- 抗凝血素-III (AT-III) 是一种重要的蛋白酶抑制剂,负责氨酸的抗凝固作用.
- 了解AT-III水平对于解释肝素治疗期间的临床数据至关重要.
研究的目的:
- 为了研究连续静脉注射肝素输液对血抗素III (AT-III) 度的影响.
- 为了确定长时间暴露于肝素是否会影响AT-III水平及其结合能力.
主要方法:
- 血AT-III度测量在26名接受肝素治疗的患者 (24连续输注,2次重复注射).
- 在整个治疗过程中评估了AT-III结合能力和抗原蛋白水平.
- 在停止服用肝素后,对AT-III水平进行了监测.
主要成果:
- 肝素治疗,特别是连续输注,导致血AT-III水平的逐渐降低.
- 即使在患有先天AT-III缺乏症的患者中也观察到AT-III的下降.
- 在停止肝素治疗后2-3天内,血AT-III水平恢复正常.
- 单剂量肝素并没有显著降低AT-III.
结论:
- 长期服用氨酸可显著消耗AT-III,影响其蛋白酶抑制剂功能.
- 在肝素治疗期间的AT-III耗尽可能导致血栓栓塞并发症的发生.
- 这些发现对于治疗肝素治疗的患者的管理具有临床意义.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...